+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cholera Vaccines Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5798021
The global cholera vaccines market size attained a value of USD 107.7 million in 2022. The market is anticipated to grow at a CAGR of 12.0% during the forecast period of 2023-2031 to attain a value of USD 297.8 million by 2031.

Cholera Vaccines Market: Introduction

Cholera vaccines are biological preparations that provide protection against cholera, a severe diarrheal disease caused by the bacterium Vibrio cholerae. The disease is transmitted through contaminated water and food, and can result in rapid dehydration, severe electrolyte imbalance, and even death if left untreated. Cholera is particularly prevalent in regions with poor sanitation, inadequate water treatment, and limited access to healthcare facilities. Vaccination is an essential tool in preventing cholera outbreaks and managing the disease in endemic regions.

Uses of Cholera Vaccines:
  • Preventive measure: Cholera vaccines are administered to individuals in areas where cholera is endemic, or where there is a risk of an outbreak, to prevent the spread of the disease
  • Travelers: Travelers to cholera-affected regions may be advised to receive the cholera vaccine to protect themselves from infection during their stay
  • Emergency response: Cholera vaccines can be used during humanitarian crises, such as natural disasters or refugee situations, where there is an increased risk of cholera outbreaks due to the disruption of water and sanitation systems
Benefits of Cholera Vaccines:
1. Disease prevention: Cholera vaccines significantly reduce the risk of infection, helping to prevent illness and the spread of the disease within communities.
2. Reduced morbidity and mortality: By preventing cholera infection, the vaccines help decrease the number of severe cases and fatalities associated with the disease.
3. Cost-effectiveness: Cholera vaccination campaigns can be more cost-effective than treating individual cases of the disease, as they help prevent the need for expensive medical interventions, such as intravenous rehydration therapy and hospitalization.
4. Strengthening public health efforts: Cholera vaccines are an important component of comprehensive public health strategies to control the disease, which also includes improving water and sanitation systems and promoting hygiene practices.
5. Support for healthcare systems: By reducing the number of cholera cases, vaccines can help ease the burden on healthcare systems in affected regions, allowing them to allocate resources more effectively.

There are currently several cholera vaccines available, including oral vaccines like Dukoral, Shanchol, and Euvichol. These vaccines typically require multiple doses to provide optimal protection, and the immunity they confer may decrease over time, necessitating periodic booster doses. It is important to note that while cholera vaccines are highly beneficial, they should not replace efforts to improve water and sanitation infrastructure, as well as promote proper hygiene practices to control the disease in the long term.

cholera Vaccines Market Segmentations

The market can be categorised into product, end user, and region.

Cholera Vaccines Market Breakup by Product

  • Dukoral
  • Shanchol
  • Vaxchora
  • Euvichol
  • Others

Cholera Vaccines Market Breakup by End User

  • Hospitals & Clinics
  • Research and Academic Laboratories
  • Others

Cholera Vaccines Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Cholera Vaccines Market Scenario

The cholera vaccines market has been experiencing steady growth, driven by several factors that contribute to the increasing demand for effective prevention measures against cholera. The market is primarily influenced by the prevalence of cholera in regions with poor sanitation, inadequate water treatment, and limited access to healthcare facilities, which increases the need for vaccination campaigns.
  • One of the primary drivers of the cholera vaccines market is the increased focus on public health initiatives by governments, non-governmental organizations, and international agencies such as the World Health Organization (WHO). These organizations have been actively engaged in implementing cholera vaccination programs in regions where the disease is endemic or at risk of outbreaks. This has led to a higher demand for cholera vaccines, as well as increased funding for their development and distribution
  • Another factor contributing to the growth of the cholera vaccines market is the rise in global travel, which exposes more individuals to cholera-affected regions. As a result, the demand for cholera vaccines among travellers has increased, leading to a wider distribution of the vaccines in travel clinics and other healthcare facilities
  • Climate change and its effects on weather patterns have also contributed to the increasing incidence of cholera outbreaks in some regions. Flooding, for example, can disrupt water and sanitation systems, leading to the contamination of water supplies and the spread of cholera. This has heightened the need for effective cholera vaccines to protect vulnerable populations and prevent the spread of the disease
  • The cholera vaccines market is segmented based on product types (such as Dukoral, Shanchol, and Euvichol), distribution channels (public healthcare providers, private healthcare providers, and travel clinics), and geographical regions (North America, Europe, Asia-Pacific, and the rest of the world). The Asia-Pacific region, in particular, has been a significant market for cholera vaccines, given the higher prevalence of the disease in certain countries within the region
  • The market is characterized by the presence of several key players, including both established pharmaceutical companies and emerging biotechnology firms, involved in the development, manufacturing, and distribution of cholera vaccines. As the demand for effective cholera vaccines continues to grow, these companies are likely to invest in research and development to improve existing vaccines and create new, more effective products
In conclusion, the cholera vaccines market is expected to maintain its growth trajectory in the coming years, driven by increased public health initiatives, global travel, and the ongoing need to prevent and control cholera outbreaks worldwide.

Key Players in the Global Cholera Vaccines Market

The report gives an in-depth analysis of the key players involved in the cholera vaccines market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Sanofi-aventis Groupe
  • Emergent BioSolutions Inc
  • Valneva SE
  • GlaxoSmithKline plc
  • Intervet Inc
  • EuBiologics Co., Ltd
  • Astellas Pharma Inc
  • Celldex Therapeutics
  • Johnson & Johnson Services Inc
  • Merck & Co. Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cholera Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cholera Vaccine Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cholera Epidemiology (2016-2031)
5.3 Europe Cholera Epidemiology (2016-2031)
5.4 Asia-Pacific Cholera Epidemiology (2016-2031)
5.5 Latin America Cholera Epidemiology (2016-2031)
5.6 Middle East & Africa Cholera Epidemiology (2016-2031)
6 Global Cholera Vaccine Market Overview
6.1 Global Cholera Vaccine Market Historical Value (2016-2022)
6.2 Global Cholera Vaccine Market Forecast Value (2023-2031)
7 Global Cholera Vaccine Market Landscape
7.1 Cholera Vaccine: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cholera Vaccine: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Cholera Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cholera Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cholera Vaccine Market Segmentation
11.1 Global Cholera Vaccine Market by Product
11.1.1 Market Overview
11.1.2 Dukoral
11.1.3 Shanchol
11.1.4 Vaxchora
11.1.5 Euvichol
11.1.6 Others
11.2 Global Cholera Vaccine Market by End User
11.2.1 Market Overview
11.2.2 Hospitals & Clinics
11.2.3 Research and Academic Laboratories
11.2.4 Others
11.3 Global Cholera Vaccine Market by Region
11.3.1 Market Overview
11.3.2 North America
11.3.3 Europe
11.3.4 Asia Pacific
11.3.5 Latin America
11.3.6 Middle East and Africa
12 North America Cholera Vaccine Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cholera Vaccine Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cholera Vaccine Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cholera Vaccine Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cholera Vaccine Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Sanofi-aventis Groupe
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Emergent BioSolutions Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Valneva SE
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 GlaxoSmithKline plc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Intervet Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 EuBiologics Co., Ltd.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Astellas Pharma Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Celldex Therapeutics.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Johnson & Johnson Services Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co. Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Cholera Vaccine - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Sanofi-Aventis Groupe
  • Emergent Biosolutions Inc.
  • Valneva Se
  • GlaxoSmithKline plc.
  • Intervet Inc.
  • Eubiologics Co. Ltd.
  • Astellas Pharma Inc.
  • Celldex Therapeutics.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.

Methodology

Loading
LOADING...

Table Information